-->

Dendritic cell based immunotherapy treatment in cancer

Initially depicted in 1973 by Ralph Steinman and Zanvil Cohn, dendritic cells (DCs) have a fundamental job of interfering with intrinsic insusceptible reactions and fostering a flexible immune response. From that point forward, DCs were viewed as the most intense antigen-displaying cells (APCs), frequently referred to as “Nature’s adjuvant,” designed to initiate credulous and memory-resistant reactions. In terms of securing and managing antigens for introduction to T cells, DCs have a prevalent limit and express abnormal quantities of costimulatory or coinhibitory atoms that determine secure initiation or anergy1. Right about 40 years after that, when the Nobel Prize for Medicine or Physiology was awarded to Ralph Steinman in 2011 for his disclosure of these essential natural immune cells, the importance of DCs was perceived.

This immunotherapy treatment helps the body battle cancer cells with its own defense mechanism. Dendritic cell therapy is often used when regular therapies have not been effective. As of late, this treatment was proposed in India and multiple patients were relieved under the supervision of the renowned Oncologist with empowering results. Be that as it may, there are common drugs that have been developed over decades for most forms of tumor. Usage of these drugs is administered and combined with unsusceptible care, since it is realized that tumor cells weakened by chemotherapy or radiation are considerably easier to decimate with invulnerable cells than with flawless tumor cells.

Type of cancer treated with dendritic cell based immunotherapy treatment

  1. Skin cancer
  2. Kidney cancer
  3. Breast cancer
  4. Pancreatic cancer
  5. Colon cancer
  6. Ovarian cancer
  7. Prostrate cancer

Stage IV cancer treatment

Dendritic cell based immunotherapy treatment has proved to be quite a success specially with no hope stage IV cancer treatment. Patients specially on stage IV cancer can try and go for dendritic cell based immunotherapy in cancer treatment.

Hospitals for dendritic cell based immunotherapy treatment in India

  1. LDG India Ltd, Gurugram
  2. APAC Biotech, Noida
  3. Dendritic cell research, New Delhi

Cost of dendritic cell based immunotherapy treatment in India

Cost of dendritic cell based immunotherapy treatment may vary from $ 8000 USD – $ 15,000 USD depending upon stage of cancer and treating doctor and hospital.

Susan Hau
Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • October 12th, 2018

Eating grapes may prevent you from cancer

Previous Post:
nxt-post

Patient from Somalia came to India for liver cancer treatment

Next Post:

Scan the code